

[illegible] $^{68}\text{Ga}]/\text{Ga-Neob 50 } \mu\text{g IV infusion to confirm eligibility}$

$[^{137}\text{La}]$ -NeoB IV infusion D1 of every cycle

● Fulvestrant 500mg IM D1 of every cycle. One additional administration on D15 of cycle 1

Ribociclib 600mg PO D1-21 per cycle

FIG. 1

Treatment period											Follow up period
Cycle of ¹⁷⁷ Lu-Ju-NeoB	Cycle 1	Cycle 2	Cycle 3	Cycle 4	Cycle 5	Cycle 6	Cycle 7	Cycle 8	Cycle 9	Cycle 10	Up to 5 years
Study day	-42 until -1	29-56	57-84	85-112	113-140	141-168	169-196... <i>(followed by x 28-day cycles)</i>	...	...	...	
Week	1 2 3 4	5 6 7 8	9 1 2 3	4 5 6 7	8 9 1 2	3 4 5 6	7 8 9 10	11 12 13 14	15 16 17 18	19 20 21 22	

- ¹⁸Ga]Ga-NeoB 50 µg IV infusion to confirm eligibility
- ¹⁷⁷Lu]Lu-NeoB IV infusion D1 of every cycle
- Fulvestrant 500mg IM D1 of every cycle. One additional administration on D15 of cycle 1
- Ribociclib 600mg PO D1-21 per cycle
- Goserelin 3.6mg SQ D1 of every cycle for pre-perimenopausal participants only

FIG. 2




FIG. 3